Table 1
Summary of clinicopathological prognostic value of MVD in EOC
| Authors | Ref | No. of patients | Monoclonal antibodies to | EOC type | Correlations, results, and conclusions. Clinicopathological or prognostic value |
|---|---|---|---|---|---|
| DFS, disease free survival; EOC, epithelian ovarian cancer; FIGO, Federation of Gynaecology and Obstetrics; MVD, microvessel density; OAS, overall survival; vWF, von Willebrandt factor. | |||||
| van Diest et al (1995) | 176 | 73 | vWF | FIGO III and IV | MVD shows no association with many other prognostic variables. In survival analysis: tendency for worse prognosis with higher MVD |
| Hollingsworth et al (1995) | 165 | 43 | CD34 | FIGO III and IV | MVD and stage are associated with DFS and OAS; higher MVD confers worse prognosis; low MVD is a predictor of DFS. MVD is therefore a useful prognostic tool |
| Amis et al (unpublished data, 2002) | 138 | 97 | vWF | Different subtypes | No higher MVD seen in malignant tumours compared with benign tumours |
| Nakanishi et al (1997) | 159 | 60 | vWF | Stage I–IV | In EOC, angiogenesis is equally stimulated regardless of stage. MVD alone does not provide prognostic information in these tumours |
| Orre et al (1998) | 137 | 56 | CD31, CD34, vWF | Serous and mucinous tumours, borderline cystadenomas, and others | The degrees of control and angiogenesis differ between ovarian tumour types. No association was found between increased MVD and poor prognosis |
| Alvarez et al (1999) | 177 | 88 | CD31, vWF | Primary EOC: serous, endometrioid, mucinous, clear cells, and undifferentiated carcinomas Stage I–IV | From MVD alone: overall median survival was 2.7 years in women with high MVD versus 7.9 years for those with low MVD. A low MVD was associated with better 5 year survival in both early stage (I/II) and advanced stage (III/IV) disease. MVD is a prognostic tool in early stage disease |
| Abulafia et al (2000) | 166 | 83 | vWF | Primary stage I invasive. Stage I low malignant potential EOC | MVD may help to differentiate between low malignant potential and invasive tumours |
| Nakayama et al (2001) | 178 | 42 | CD34 | Stage I–IV serous, mucinous and others | No significant prognostic value of MVD was found for patients with EOC. MVD had no influential effects on the survival of patients with EOC |
| Ogawa et al (2002) | 179 | 105 | CD34 | Primary EOC. Stage I–IV | In EOC, MVD is an independent prognostic factor. Higher MVD with clear cell adenocarcinoma had the better prognosis |
